Transgene appoints two experienced oncology executives to drive next phase of innovation Page 1

Newly appointed CMO, Dr. Emmanuelle Dochy, and newly appointed CSO, Dr. Maurizio Ceppi, bring a strong track record of advancing cancer immunotherapies and precision medicine through clinical development as Transgene advances its innovative preclinical and clinical pipeline, including the personalized therapeutic cancer vaccine TG4050.

Strasbourg, France, 10 September 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased announce the appointment of two experienced oncology leaders who will make a significant contribution to the further development of the company’s innovative immunotherapy programs. Emmanuelle Dochy, MD, appointed Chief Medical Officer (CMO) and Maurizio Ceppi, PhD, is appointed Chief Scientific Officer (CSO) with immediate effect.